Shilpa Medicare Overview

  • Year Founded
  • 1987

Year Founded

  • Status
  • Public

  • Employees
  • 3,074

Employees

  • Stock Symbol
  • 530549

Stock Symbol

  • Investments
  • 15

  • Share Price
  • $9.96
  • (As of Monday Closing)

Shilpa Medicare General Information

Description

Shilpa Medicare Ltd is a specialty and generic drug manufacturer. The company deals in high-quality Active Pharmaceutical Ingredients (APIs), Intermediates, Formulations, New Drug Delivery Systems, Peptides, Biotech products, and Specialty Chemicals etc. Its portfolio comprises various oncology and non-oncology-related APIs such as anastrozole, acebrophylline, busulphan, decitabine, etc, and finished dosage formulations such as apremilast tablets, clofarabine injection, docetaxel injection, etc., in various therapy areas. Its reporting segments are: Pharmaceutical product and services, which derive maximum revenue, Power sales, and Others. Geographically, the company generates maximum revenue from India, followed by Europe, the United States of America, and the Rest of the world.

Contact Information

Formerly Known As
Shilpa Antibiotics
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • Suite 12-6-214/A1
  • Hyderabad Road
  • Raichur, Karnataka 584135
  • India
+91 085322
Primary Industry
Other Pharmaceuticals and Biotechnology
Stock Exchange
BOM
Corporate Office
  • Suite 12-6-214/A1
  • Hyderabad Road
  • Raichur, Karnataka 584135
  • India
+91 085322

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Shilpa Medicare Stock Performance

As of 16-Nov-2026, Shilpa Medicare’s stock price is $9.96. Its current market cap is $1.95B with 196M shares.

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$9.96 $10.56 $2.83 - $11.42 $1.95B 196M 63.8K $0.18

Shilpa Medicare Financials Summary

As of 30-Sep-2026, Shilpa Medicare has a trailing 12-month revenue of $199M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2026 31-Mar-2026 FY 2025 31-Mar-2025 FY 2024 31-Mar-2024
EV 2,193,785 776,515 808,551 579,370
Revenue 198,623 174,052 151,943 139,014
EBITDA 62,494 52,166 35,814 29,539
Net Income 35,854 27,537 9,259 3,850
Total Assets 430,765 392,741 387,036 370,921
Total Debt 69,339 69,936 68,712 112,405
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Shilpa Medicare Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Shilpa Medicare‘s full profile, request access.

Request a free trial

Shilpa Medicare Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Shilpa Medicare Ltd is a specialty and generic drug manufacturer. The company deals in high-quality Active Pharmaceutica
Other Pharmaceuticals and Biotechnology
Raichur, India
3,074 As of 2026

Mumbai, India
 

Hyderabad, India
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Shilpa Medicare Competitors (33)

One of Shilpa Medicare’s 33 competitors is Aarti Drugs, a Corporation company based in Mumbai, India.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Aarti Drugs Corporation Mumbai, India
Neuland Laboratories Corporation Hyderabad, India
Marksans Pharma Corporation Mumbai, India
Gland Pharma Formerly PE-Backed Hyderabad, India
Lonza Group Corporation Basel, Switzerland
You’re viewing 5 of 33 competitors. Get the full list »

Shilpa Medicare Patents

Shilpa Medicare Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20260272886-A1 Ondansetron extendable release injectable suspension and methods of use Pending 11-Mar-2025
WO-2026190541-A1 Ondansetron extendable release injectable suspension and methods of use Pending 11-Mar-2025
US-20250114342-A1 Apixaban oral liquid dosage forms Pending 04-Oct-2023
WO-2024105521-A1 Stable peptide pharmaceutical composition Inactive 17-Nov-2022
AU-2023313512-A1 Pharmaceutical compositions of nor-udca Pending 25-Jul-2022 A61K9/2054
To view Shilpa Medicare’s complete patent history, request access »

Shilpa Medicare Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Shilpa Medicare Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Shilpa Medicare‘s full profile, request access.

Request a free trial

Shilpa Medicare Investments & Acquisitions (15)

Shilpa Medicare’s most recent deal was a Corporate with Gate2Brain for . The deal was made on 03-Jun-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Gate2Brain 03-Jun-2026 Corporate Drug Discovery
Alveolus Bio 04-Aug-2025 Later Stage VC Drug Discovery
Pilnova Pharma 02-Nov-2023 Merger/Acquisition Media and Information Services (B2B)
FTF Pharma 02-Nov-2020 Merger/Acquisition Drug Discovery
Auxilla Pharmaceuticals and Research 16-Jun-2020 Corporate Drug Delivery
You’re viewing 5 of 15 investments and acquisitions. Get the full list »

Shilpa Medicare ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

33.27 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Pharmaceuticals

Subindustry

of 354

Rank

Percentile

To view Shilpa Medicare’s complete esg history, request access »

Shilpa Medicare Exits (2)

Shilpa Medicare’s most recent exit was on 23-Apr-2013 from MAIA Pharmaceuticals. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
MAIA Pharmaceuticals 23-Apr-2013 Completed
Loba biotech 31-Mar-2008 Buyout/LBO Completed
  • 4 buyers
To view Shilpa Medicare’s complete exits history, request access »

Shilpa Medicare Affiliates

Subsidiaries (2)

Name Industry Location Year Founded
Shilpa Pharma Lifesciences Raichur, India 2022
FTF Pharma Ahmedabad, India 2012

Shilpa Medicare FAQs

  • When was Shilpa Medicare founded?

    Shilpa Medicare was founded in 1987.

  • Where is Shilpa Medicare headquartered?

    Shilpa Medicare is headquartered in Raichur, India.

  • What is the size of Shilpa Medicare?

    Shilpa Medicare has 3,074 total employees.

  • What industry is Shilpa Medicare in?

    Shilpa Medicare’s primary industry is Other Pharmaceuticals and Biotechnology.

  • Is Shilpa Medicare a private or public company?

    Shilpa Medicare is a Public company.

  • What is Shilpa Medicare’s stock symbol?

    The ticker symbol for Shilpa Medicare is 530549.

  • What is the current stock price of Shilpa Medicare?

    As of 16-Nov-2026 the stock price of Shilpa Medicare is $9.96.

  • What is the current market cap of Shilpa Medicare?

    The current market capitalization of Shilpa Medicare is $1.95B.

  • What is Shilpa Medicare’s current revenue?

    The trailing twelve month revenue for Shilpa Medicare is $199M.

  • Who are Shilpa Medicare’s competitors?

    Aarti Drugs, Neuland Laboratories, Marksans Pharma, Gland Pharma, and Lonza Group are some of the 33 competitors of Shilpa Medicare.

  • What is Shilpa Medicare’s annual earnings per share (EPS)?

    Shilpa Medicare’s EPS for 12 months was $0.18.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process